Murine cytomegalovirus retinitis during MAIDS: Susceptibility correlates with elevated intraocular levels of interleukin-4 mRNA

Current Eye Research

Volumn 26, Issue 3-4, 2003, Pages 211-217

  Dix, Richard D ^a   Cousins, Scott W ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Cytomegalovirus retinitis; Interleukin 2; Interleukin 4; Murine AIDS (MAIDS); Murine cytomegalovirus

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 4; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETINITIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RODENT DISEASE; SPLEEN; SPLEEN CELL;

ANIMALS; COMPUTER SYSTEMS; CYTOMEGALOVIRUS RETINITIS; DISEASE SUSCEPTIBILITY; EYE; HERPESVIRIDAE INFECTIONS; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME; MUROMEGALOVIRUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPLEEN;

EID: 0038575291     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.26.3.211.14902     Document Type: Conference Paper

References (38)

1. Cunningham ET, Margolis TP. Ocular manifestations of HIV infection. N Engl J Med. 1998;339:236-244.
2. Bloom JN, Palestine AG. The diagnosis of cytomegalovirus retinitis. Ann Intern Med. 1988;15:963-969.
3. Fay MT, Freeman WR, Wiley CA, Hardy D, Bozzette S. Atypical retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988;105:483-490.
4. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989;107:75-80.
5. Jabs DA, Bartlett JG. AIDS and ophthalmology: A period of transition. Am J Ophthalmol. 1997;124:227-233.
6. Palella FJ Jr, Delaney KM, Moorman AC, Loveless JO, Fuhrer J, Satten DJ, Aschman J, Homberg SD, and the HIV Outpatient Study. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
7. Jacobson MA, Stanley S, Holtzer C, Margolis TP, Cunningham ET. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30:232-233.
8. Dix RD, Cray C, Cousins SW. Mice immunosuppressed by murine retrovirus infection (MAIDS) are susceptible to cytomegalovirus retinitis. Curr Eye Res. 1994;13:587-595.
9. Morse III HC, Chattopadhyay SK, Makino M, Fredrickson TN, Hugin AW, Hartley JW. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model of AIDS. AIDS. 1992;6:607-621.
10. Dix RD, Giedlin M, Cousins SW. Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency. Invest Ophthalmol Vis Sci. 1997;38:1411-1417.
11. Smith KA. Interleukin-2: Inception, impact, and implications. Science. 1988;240:1169-1176.
12. Kagi D, Vignaux F, Ledermann B, Burki K, Depraitere V, Nagata S, Hengartner H, Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994;265:528-530.
13. Smyth MJ, Trapani JA. The relative role of lymphocyte granule exocytosis versus death receptor-mediated cytotoxicity in viral pathophysiology. J Virol. 1998;72:1-9.
14. Dix RD, Podack ER, Cousins SW. Loss of the perforin cytotoxic pathway predisposes mice to experimental cytomegalovirus retinitis. J Virol. 2003; (in press).
15. Dix RD, Podack ER, Cousins SW. Murine cytomegalovirus retinitis during retrovirus-induced immunodeficiency in mice (MAIDS): Interleukin-2 immunotherapy correlates with increased intraocular levels of perforin mRNA. Antiviral Res 2003; (in press).
16. Clerici M, Shearer GM. A TH1-TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14:107-111.
17. Villacres M, Bergmann CC. Enhanced cytotoxic T cell activity in IL-4-deficient mice. J Immunol. 1999;162:2663-2670.
18. Aung S, Graham BS. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity in vivo. J Immunol. 2000;164:3487-3493.
19. Gazzinelli RT, Makino M, Chattopadhyay SK, Snapper CM, Sher A, Hugin AW, Morse III HC. CD4+ subset regulation in viral infection: Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice. J Immunol. 1992;148:182-188.
20. Deng G, Podack ER. Suppression of apoptosis in a cytotoxic T-cell line by interleukin-2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad Sci USA. 1993;90:2189-2193.
21. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000;25:169-193.
22. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med. 2001;250:462-475.
23. Atkins MB. Interleukin-2: Clinical applications. Seminars in Oncology. 2002;29:12-17.
24. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr, Walker RE, Polis MA Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC. Controlled trial of interleukin-2 infusions in patients with the human immunodeficiency virus. N Engl J Med. 1996;335:1350-1356.
25. Davey RT Jr, Chaitt DG, Albert JM, Piscetelli SC, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Dewar R, Baseler M, Fyfe G, Giedlin MA, Lane HC. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early immunodeficiency virus type 1 infection. J Infect Dis. 1999;179:849-858.
26. Kovacs JA, Vogel S, Metcalf JA, Baseler M, Stevens R, Adelsberger J, Lempicki R, Hengel RL, Sereti I, Lambert L, Dewar RL, Davey RT Jr, Walker RE, Falloon J, Polis MA, Masur H, Lane HC. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur J Immunol. 2001;31:1351-1360.
27. Mitsuyasu RT. The potential role of interleukin-2 in HIV. AIDS. 2001;15(Suppl 2):S22-S27.
28. Aung S, Tang Y-W, Graham BS. IL-4 diminishes CD8+ respiratory syncytial virus (RSV)-specific cytotoxic T lymphocyte activity in vivo. J Virol. 1999;73:8944-8949.
29. Fischer JE, Johnson JE, Kuli-Zade RK, Johnson TR, Aung S, Parker RA, Graham BS. Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J Virol. 1997;71:8672-8677.
30. Moran TM, Isobe H, Fernandez-Sesma A, Schulman JL. Interleukin-4 causes delayed viral clearance in influenza virus-infected mice. J Virol. 1996;70:5230-5235.
31. Sharma EP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol. 1996;70:7103-7107.
32. Aung S, Graham BS. IL-4 diminsihes perforin-mediated and increases Fas ligand-mediated cytotoxicity in vivo. J Immunol. 2000;164:3487-3493.
33. Cousins SW, Rouse BT Chemical mediators of ocular inflammation. In Ocular Infection & Immunity (Eds Pepose JS, Holland GN, Wilhelmus KR). Pp. 50-70, Mosby Press, St. Louis, MO. 1996.
34. Charteris DG, Lightman SL. Comparison of the expression of interferon gamma, IL2, IL4, and lymphotoxin mRNA in experimental autoimmune uveoretinitis. Br J Ophthalmol. 1994;78:786-790.
35. Keino H, Takeuchi J, Suzuki J, Kojo S, Sakai J, Nishioka K, Sumida T, Usui M. Identification of Th2-type suppressor T cells among in vivo expanded ocular T cells in mice with experimental autoimmune uveoretinitis. Clin Exp Immunol. 2001;124:1-8.
36. Verjans GMGM, Feron EJ, Dings MEM, Cornelissen JGC, Van der Lelij A, Baarsman GS, Osterhaus ADME. T cells specific for the triggering virus infiltrate in the eye in patients with herpes simplex virus-mediated acute retinal necrosis. J Infect Dis. 1998;178:27-34.
37. Ghiasi H, Cai S Slanina SM, Guey-Chuen P, Nesburn AB, Wechsler SL. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. J Infect Dis. 1999;179:1086-1093.
38. Sad S, Mosmann TR. IL-4, in the absence of antigen stimulation, induces an anergy-like state in differentiated CD8+ Tcl cells, loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines. J Exp Med. 1995;182:1505-1511.